Eur Rev Med Pharmacol Sci 2021; 25 (1): 71-77
DOI: 10.26355/eurrev_202101_24350

Nano-TiO2 particles inhibit the biological behavior and mineralization of bone marrow mesenchymal stem cells transfected with CXCR4

H. Hu, L. Chen, S.-T. Li, Q.-Y. Pan, Y.-P. Liu

Department of General Surgery, The Fifth Hospital of Wuhan, Wuhan, Hubei, China. whdwyykjk@163.com


OBJECTIVE: Bone marrow mesenchymal stem cells (BMSC) are widely used as experimental cells with potential differentiation function. Nanomaterials are currently a research hotspot. We assessed nano-TiO2 particles’ effect on the biological behavior and mineralization of CXCR4 transfected BMSCs.

PATIENTS AND METHODS: After transfection of BMSC with CXCR4, cells were divided into blank group (no transfection), control group (transfection with CXCR4) and observe group (transfection with CXCR4 containing nanoparticles). Then, cell proliferation and ALP staining were measured along with analysis of Runx2 and BGP level by Western blot or RT-PCR and mineralization detection.

RESULTS: With increased culture time, the observed fractionation on day 14 showed significantly reduced activity; 3 mn nano-TiO2 particles significantly inhibited cell proliferation and bone formation after CXCR4 transfection with an inhibitory effect on the osteogenic ability of CXCR4-transfected BMCS cells in a time-dependent manner. The longer the culture time, the more significantly inhibitory effect; 3 mn nano-TiO2 particles can inhibit the mineralization of BMSCs after transfection of CXCR4 to a certain extent.

CONCLUSIONS: TiO2 nanoparticles have an inhibitory effect on the biological behavior and mineralization of BMSC cells transfected with CXCR4. The longer the culture time, the greater the inhibitory effect on osteogenic differentiation of BMSC cells transfected with CXCR4.

 

Free PDF Download

To cite this article

H. Hu, L. Chen, S.-T. Li, Q.-Y. Pan, Y.-P. Liu
Nano-TiO2 particles inhibit the biological behavior and mineralization of bone marrow mesenchymal stem cells transfected with CXCR4

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 1
Pages: 71-77
DOI: 10.26355/eurrev_202101_24350